Chicago, IL, April 24, 2014 — (Techsonian) – IAMGOLD Corp (USA) (NYSE:IAG) will declare its first quarter 2014 financial outcome after market hours on Tuesday, May 6th, 2014. A conference call will be held on Wednesday, May 7th at 8:30 a.m. (Eastern Daylight Time) for a discussion with management regarding the Company’s operating performance and financial outcome for the first quarter of 2014.
IAMGOLD Corp (USA) (NYSE:IAG) closed latest trading day at $3.55, up +2.90%, on volume of over 4.18 million shares. The stock went up 1.43% in the last 5 days. Its average trading volume is 6.21 million shares. In the time frame of the last one month, the share-price has plunged almost -5.33%. Its market capitalization was $1.34 billion.
For How Long IAG will Fight for Profitability? Read This Trend Analysis report
Exelixis, Inc. (NASDAQ:EXEL) reported that the Independent Data Monitoring Committee (IDMC) notified the company that a planned interim analysis of the COMET-1 phase 3 pivotal trial has been completed, and that the IDMC recommended the trial proceed to its final analysis. Exelixis continues to anticipate top-line data from COMET-1 in 2014.
Shares of Exelixis, Inc. (NASDAQ:EXEL) traded in a range of $3.39 to $3.60, completing the day down -3.63% to $3.45. The total volume of shares exchanged was 4.04 million. The day started out with an opening price of $3.59. The company has the total of 194.68 million outstanding shares while its market capitalization is now about $671.66 million.
Has EXEL Found The Bottom And Ready To Gain Momentum? Find Out Here
Geron Corporation, (NASDAQ:GERN) a clinical stage biopharmaceutical company, develops a telomerase inhibitor, imetelstat, to treat hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California.
Geron Corporation (NASDAQ:GERN) finished last trade at $2.00, falling -8.68%. Trading volume recorded for this company was about 3.78 million shares as compared to its average volume of 8.04 million shares. The share price plunged almost -9.5% in the last one month while its 52 week high is $7.79. The company has the total of 156.90 million outstanding shares while its market capitalization is now about $313.80 million.
Why Should Investors Buy GERN After the Recent Fall? Just Go Here and Find Out
Gevo, (NASDAQ:GEVO) recently declared its financial outcome for the three months ended December 31, 2013 and provided an update on recent corporate highlights. The Company is focused on the development and commercialization of alternatives to petroleum-based products.
Gevo, Inc. (NASDAQ:GEVO) traded with -7.63% lost momentum to $1.09 in the latest trading session It captured $74.71 million in market value. The total number of shares traded on the latest trading day was about 3.65 million shares. The day started out with an opening price of $1.16 and changed hands at price range of $1.04 to $1.23 apiece.
Will GEVO Get Buyers Even After The Recent Decline? Find Out Here